Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Change in Acquisitions & Divestments (2017 - 2025)

Editas Medicine (EDIT) has disclosed Change in Acquisitions & Divestments for 9 consecutive years, with $40.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Change in Acquisitions & Divestments fell 53.96% to $40.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $170.5 million, a 48.11% decrease, with the full-year FY2024 number at $257.2 million, down 0.89% from a year prior.
  • Change in Acquisitions & Divestments was $40.0 million for Q3 2025 at Editas Medicine, down from $42.5 million in the prior quarter.
  • In the past five years, Change in Acquisitions & Divestments ranged from a high of $130.8 million in Q1 2021 to a low of $31.5 million in Q4 2024.
  • A 5-year average of $76.4 million and a median of $74.2 million in 2021 define the central range for Change in Acquisitions & Divestments.
  • Peak YoY movement for Change in Acquisitions & Divestments: surged 176.48% in 2021, then tumbled 69.39% in 2024.
  • Editas Medicine's Change in Acquisitions & Divestments stood at $84.3 million in 2021, then fell by 6.91% to $78.5 million in 2022, then surged by 31.08% to $102.9 million in 2023, then crashed by 69.39% to $31.5 million in 2024, then increased by 27.03% to $40.0 million in 2025.
  • Per Business Quant, the three most recent readings for EDIT's Change in Acquisitions & Divestments are $40.0 million (Q3 2025), $42.5 million (Q2 2025), and $56.5 million (Q1 2025).